To Evaluate Safety and Effectiveness of RovatitanTab.

NCT04398771 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2020-05-21

No results posted yet for this study

Summary

To evaluate the safety and effectiveness of a fixed-dose combination containing valsartan and rosuvastatin (Rovatitan® Tablet) in patient with hypertension and hypercholesterolemia

Conditions

Interventions

DRUG

Rosuvastatin/Valsartan

Rovatitan QD for 12 weeks

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • Kang seokmin · Severance Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2022-01-31
Completion
2022-05-31

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398771 on ClinicalTrials.gov